Provexis（NZCA）株式概要Provexis plcは子会社とともに、機能性食品、医療用食品、栄養補助食品の開発、ライセンス供与、販売を世界中で行っている。 詳細NZCA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間13.2%減少しました。 German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある収益がありません ( £871K )意味のある時価総額がありません ( €34M )すべてのリスクチェックを見るNZCA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW498,766 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG498,766 investors already sharing narrativesYour Fair Value€Current Price€0.011450.0% 割高 内在価値ディスカウントEst. Revenue$PastFuture-604k3m2016201920222025202620282031Revenue UK£2.7mEarnings UK£283.6kAdvancedSet Fair ValueView all narrativesProvexis plc 競合他社Biome AustraliaSymbol: ASX:BIOMarket cap: AU$59.3mHealthy ExtractsSymbol: OTCPK:HYEXMarket cap: US$29.6mBBIASymbol: KOSDAQ:A451250Market cap: ₩70.4bLSL Pharma GroupSymbol: TSXV:LSLMarket cap: CA$41.8m価格と性能株価の高値、安値、推移の概要Provexis過去の株価現在の株価UK£0.01152週高値UK£0.0252週安値UK£0.0005ベータ0.671ヶ月の変化37.50%3ヶ月変化1,000.00%1年変化2,100.00%3年間の変化100.00%5年間の変化37.50%IPOからの変化-76.09%最新ニュースBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025お知らせ • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomReported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomNew Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m).最新情報をもっと見るRecent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025お知らせ • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomReported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomNew Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m).New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$17.8m).Reported Earnings • Oct 01Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022)Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Provexis plc, Annual General Meeting, Oct 26, 2023Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters.New Risk • Jul 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (€14.8m market cap, or US$16.2m).Reported Earnings • Dec 31First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022)First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 14Provexis plc Announces Directorate ChangeProvexis, announced the resignation of Frédéric Boned, a Non-executive Director of the Company, with immediate effect. Frédéric Boned joined the Board of Provexis as a Non-executive Director in July 2018, at which point he was EMEA Vice President of DSM's Human Nutrition & Health business, a part of DSM Nutritional Products. Frédéric, who is currently Regional Vice President Health Nutrition & Care North America at DSM, has announced his resignation from DSM with effect from 15 October 2022.Reported Earnings • Oct 01Full year 2022 earnings releasedFull year 2022 results: Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021).お知らせ • Oct 01+ 1 more updateProvexis plc to Report Q1, 2023 Results on Sep 30, 2022Provexis plc announced that they will report Q1, 2023 results on Sep 30, 2022お知らせ • Jun 22Provexis plc Announces the Filing of New Patent ApplicationProvexis plc announced the filing of a new patent application relating to the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans. This follows the completion of a successful human study, the results of which (as stated in the patent application) strongly support the use of Fruitflow for modulating gut microbiota to confer a number of health benefits.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Nov 16Provexis plc Announces Exclusive Distribution Agreement for Chinese CBECProvexis announced it has entered into a distribution agreement with a company ('the Distributor') which will act as the distributor for Fruitflow+ Omega-3 in China, exclusively through the Chinese Cross-Border e-commerce ('CBEC') channel. CBEC regulations include a waiver of the existing Chinese pre-importation registration requirements on specified categories of products, permitting overseas exporters to sell consumer goods directly to Chinese consumers through certain registered e-commerce platforms. The agreement announced grants the Distributor exclusive rights to import, market and sell the Company's Fruitflow+ Omega-3 dietary supplement product in China through the CBEC channel, with immediate effect. The Distributor will purchase Fruitflow+ Omega-3 as required from the Company, and the Distributor will then market and sell Fruitflow+ Omega-3 in China through its existing network of e-commerce and other sales channels. The Company has recently completed a redesign of the existing Fruitflow+ Omega-3 packaging, to include a new single blister pack format, with this new packaging having been optimised for sales through CBEC by the Distributor in China.Reported Earnings • Oct 01Full year earnings released - €0.0002 loss per shareOver the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year.株主還元NZCADE Personal ProductsDE 市場7D0%-2.4%-1.2%1Y2,100.0%-3.3%0.5%株主還元を見る業界別リターン: NZCA過去 1 年間で-3.3 % の収益を上げたGerman Personal Products業界を上回りました。リターン対市場: NZCA過去 1 年間で0.5 % の収益を上げたGerman市場を上回りました。価格変動Is NZCA's price volatile compared to industry and market?NZCA volatilityNZCA Average Weekly Movement596.1%Personal Products Industry Average Movement5.0%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.8%安定した株価: NZCAの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: NZCAの 週次ボラティリティ は過去 1 年間で670%から596%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19992Ian Fordwww.provexis.comProvexis plcは、その子会社とともに、世界中で機能性食品、医療用食品、栄養補助食品の開発、ライセンス供与、販売を行っている。同社は、様々な食品、飲料、栄養補助食品に使用される心臓発作や脳卒中などの心血管疾患に典型的に関連する異常な血液凝固の傾向を低減するトマト抽出物、Fruitflowのシロップと粉末バージョンを提供しています。また、栄養補助食品としてFruitflow+ Omega-3も提供している。同社はウェブサイトや代理店を通じて製品を販売している。Provexis plcは1999年に設立され、英国レディングに本社を置いている。もっと見るProvexis plc 基礎のまとめProvexis の収益と売上を時価総額と比較するとどうか。NZCA 基礎統計学時価総額€33.54m収益（TTM）-€707.64k売上高(TTM)€1.02m32.8xP/Sレシオ-47.4xPER（株価収益率NZCA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NZCA 損益計算書（TTM）収益UK£871.27k売上原価UK£442.30k売上総利益UK£428.97kその他の費用UK£1.03m収益-UK£603.80k直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.00026グロス・マージン49.24%純利益率-69.30%有利子負債／自己資本比率0%NZCA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 20:48終値2026/07/14 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Provexis plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025
お知らせ • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
Reported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
New Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m).
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025
お知らせ • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
Reported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
New Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m).
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$17.8m).
Reported Earnings • Oct 01Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022)Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Provexis plc, Annual General Meeting, Oct 26, 2023Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters.
New Risk • Jul 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (€14.8m market cap, or US$16.2m).
Reported Earnings • Dec 31First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022)First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 14Provexis plc Announces Directorate ChangeProvexis, announced the resignation of Frédéric Boned, a Non-executive Director of the Company, with immediate effect. Frédéric Boned joined the Board of Provexis as a Non-executive Director in July 2018, at which point he was EMEA Vice President of DSM's Human Nutrition & Health business, a part of DSM Nutritional Products. Frédéric, who is currently Regional Vice President Health Nutrition & Care North America at DSM, has announced his resignation from DSM with effect from 15 October 2022.
Reported Earnings • Oct 01Full year 2022 earnings releasedFull year 2022 results: Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021).
お知らせ • Oct 01+ 1 more updateProvexis plc to Report Q1, 2023 Results on Sep 30, 2022Provexis plc announced that they will report Q1, 2023 results on Sep 30, 2022
お知らせ • Jun 22Provexis plc Announces the Filing of New Patent ApplicationProvexis plc announced the filing of a new patent application relating to the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans. This follows the completion of a successful human study, the results of which (as stated in the patent application) strongly support the use of Fruitflow for modulating gut microbiota to confer a number of health benefits.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Nov 16Provexis plc Announces Exclusive Distribution Agreement for Chinese CBECProvexis announced it has entered into a distribution agreement with a company ('the Distributor') which will act as the distributor for Fruitflow+ Omega-3 in China, exclusively through the Chinese Cross-Border e-commerce ('CBEC') channel. CBEC regulations include a waiver of the existing Chinese pre-importation registration requirements on specified categories of products, permitting overseas exporters to sell consumer goods directly to Chinese consumers through certain registered e-commerce platforms. The agreement announced grants the Distributor exclusive rights to import, market and sell the Company's Fruitflow+ Omega-3 dietary supplement product in China through the CBEC channel, with immediate effect. The Distributor will purchase Fruitflow+ Omega-3 as required from the Company, and the Distributor will then market and sell Fruitflow+ Omega-3 in China through its existing network of e-commerce and other sales channels. The Company has recently completed a redesign of the existing Fruitflow+ Omega-3 packaging, to include a new single blister pack format, with this new packaging having been optimised for sales through CBEC by the Distributor in China.
Reported Earnings • Oct 01Full year earnings released - €0.0002 loss per shareOver the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year.
